【Suzuken】2026 Financial Results｜Sales of ¥2.4866 Trillion, 10.6% Increase in Net Income

Performance Overview

Suzuken recorded net sales of ¥2.4866 trillion (up 3.6% YoY) and net income attributable to owners of the parent of ¥38.136 billion (up 10.6%) for the fiscal year ending March 2026. While expanding due to growth in the pharmaceutical market and contributions from new drugs, operating income decreased due to rising costs and procurement prices. The pharmaceutical wholesale segment remains primary, with efforts to expand specialty drug distribution and strengthen logistics infrastructure. Moving forward, the company will continue to transform existing businesses and develop new ones in line with its mid-term management plan to achieve sustainable growth.

Future Outlook and Shareholder Returns

For the fiscal year ending March 2027, earnings are projected to be net sales of ¥2.563 trillion (up 3.1% YoY) and net income of ¥25 million (down 34.4%). The company will address environmental changes by promoting next-generation wholesale and reconfiguring its business portfolio. Shareholder returns are planned to include a dividend of ¥120 (interim ¥60, final ¥60), with a stock split also scheduled. Key initiatives in the mid-term management plan include strengthening business functions and enhancing management foundation, with a focus on sustainable growth and increasing corporate value.